Company Gaining Traction with Drug Candidate CVSI-007 to Become the Only FDA Approved Treatment for Smokeless Tobacco Addiction
LAS VEGAS, NV – (Marketwired – July 20, 2017) – CV Sciences, Inc. (OTCQB: CVSI) (the “Company,” “CV Sciences,” “our” or “we”), highlights a recent clinical study using pharmaceutical grade cannabidiol (CBD) which suggests that CBD may be effective in blunting the rise in blood pressure associated with stress. A June 2017 report published in the Journal of Clinical Investigation Insight stated, “a single dose of cannabidiol reduces blood pressure in healthy volunteers in a randomized crossover study.”
Investigators from the United Kingdom studied the effects of single doses of CBD on blood pressure after dosing nine healthy volunteers with 600mg of oral CBD or placebo in a randomized, placebo-controlled, double-blind, crossover study. The study showed that CBD significantly reduced systolic blood pressure (P<0.05) as well as diastolic blood pressure and mean arterial blood pressure as compared with placebo (P<0.01 120-160 minutes after treatment) while maintaining cardiac output, and that CBD reduced the increased blood pressure response to stress induced by mental exercise, physical exercise, and cold (P<0.05).
As the quality of clinical investigations into pharmaceutical-grade CBD improves, research is disclosing more about its effects and benefits on overall health.
CV Sciences is currently in development of a patent-pending method of using CBD as an adjunct to nicotine replacement therapy (NRT) for smokeless tobacco addiction. One of the well-established acute side effects of nicotine, whether delivered as tobacco or as NRT, is an increase in blood pressure. Based on this recent clinical study, it may be that CBD can help to blunt the nicotine-induced increase in blood pressure. At the same time, the Company believes that the adjunctive use of CBD with NRT will reduce the amount of nicotine required to satisfy the cravings of those addicted to smokeless tobacco, which could enhance its effects on moderating blood pressure during treatment for smokeless tobacco addiction.
According to Statista, there was approximately $5.3 billion in retail sales of smokeless tobacco products in 2014 and approximately 1.3 billion units of smokeless tobacco products sold during that time. CV Sciences believes that its initial drug candidate to treat smokeless tobacco addiction can dramatically improve patient outcomes for millions. Currently the smokeless tobacco cessation market is estimated at $2 billion, growing to over $4 billion.
About CV Sciences, Inc.
CV Sciences, Inc. (OTCQB: CVSI) operates two distinct business segments: a drug development division focused on developing and commercializing novel therapeutics utilizing synthetic CBD; and a consumer product division in manufacturing, marketing and selling plant-based CBD products to a range of market sectors. CV Sciences, Inc. has primary offices and facilities in San Diego, California and Las Vegas, Nevada. Additional information is available from OTCMarkets.com or by visiting www.cvsciences.com.
This press release may contain certain forward-looking statements and information, as defined within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, and is subject to the Safe Harbor created by those sections. This material contains statements about expected future events and/or financial results that are forward-looking in nature and subject to risks and uncertainties. Such forward-looking statements by definition involve risks, uncertainties.